454 Installs Twenty GS20 Systems in the First Year of Sales
News Jan 13, 2006
The Genome Sequencer 20 system was developed by 454 Life Sciences and recognized by the Wall Street Journal with the overall and biotechnology Gold Medals in its 2005 Technology Innovation Awards.
Chris McLeod, President and CEO of 454 Life Sciences comments, "We are pleased to have Roche Applied Science as our exclusive distribution partner and research collaborator."
"In the fourth quarter, we more than doubled the number of installed instrument systems at research centers around the world and have had repeat customers currently using multiple GS20 systems."
"This has been one of our most successful product launches ever," commented Volker Pfahlert, Head of Roche Applied Science.
"It is clear that the Genome Sequencer 20 system addresses the need for rapid, high-throughput sequencing in numerous life science applications."
454 Life Sciences financial results for 2005 and guidance for 2006 will be reported on February 2, 2006 in conjunction with CuraGen Corporation's fourth quarter and 2005 year-end results press release.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.